Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
16.53
-0.59 (-3.45%)
Oct 29, 2025, 10:51 AM EDT - Market open
CRBP Employees
Corbus Pharmaceuticals Holdings had 28 employees as of December 31, 2024. The number of employees increased by 9 or 47.37% compared to the previous year.
Employees
28
Change (1Y)
9
Growth (1Y)
47.37%
Revenue / Employee
n/a
Profits / Employee
-$2,069,750
Market Cap
202.58M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28 | 9 | 47.37% |
| Dec 31, 2023 | 19 | -14 | -42.42% |
| Dec 31, 2022 | 33 | -8 | -19.51% |
| Dec 31, 2021 | 41 | -35 | -46.05% |
| Dec 31, 2020 | 76 | -65 | -46.10% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CRBP News
- 8 days ago - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel Transcript - Seeking Alpha
- 11 days ago - Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25 - GlobeNewsWire
- 6 weeks ago - FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma - GlobeNewsWire
- 4 months ago - Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab - GlobeNewsWire
- 4 months ago - Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium - GlobeNewsWire
- 4 months ago - Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data? - Seeking Alpha
- 5 months ago - Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 months ago - Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair - GlobeNewsWire